%0 Journal Article
%T PRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma
%A Guo-Zhen Shi
%A Yang Yuan
%A Guo-Jun Jiang
%A Zhi-Jun Ge
%A Jian Zhou
%A De-Jun Gong
%A Jing Tao
%A Yong-Fei Tan
%A Sheng-Dong Huang
%J BMC Cancer
%D 2012
%I BioMed Central
%R 10.1186/1471-2407-12-97
%X The expression of PRAF3 mRNA and protein in primary ESCC and the matched normal tissues (57cases) was determined by quantitative RT-PCR and Western blot. Immunohistochemical analysis of PRAF3 expression was carried out in paraffin-embedded sections of ESCC and correlated with clinical features. The role of PRAF3 in apoptosis, migration and invasion was studied in ESCC cell lines of Eca109 and TE-1 through the adenovirus mediated PRAF3 gene transfer. The effect of PRAF3 on apoptosis was analyzed by annexin V-FITC assay. The regulation of PRAF3 on migration was determined by transwell and wounding healing assay, while the cellular invasion was analyzed by matrigel-coated transwell assay.We found that the expression of PRAF3 was significantly down-regulated in ESCC tissue compared with the matched normal tissue and was correlated with the clinical features of pathological grade, tumor stage and lymph node metastasis. Moreover, overexpression of PRAF3 induced cell apoptosis through both caspase-8 and caspase-9 dependent pathways, and inhibited cell migration and invasion by suppressing the activity of both MMP-2 and MMP-9 in human ESCC cell lines.Our data suggest that PRAF3 plays an important role in the regulation of tumor progression and metastasis and serves as a tumor suppressor in human ESCC. We propose that PRAF3 might be used as a potential therapeutic agent for human ESCC.Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China, Japan, and southeast Africa [1,2]. Although novel surgical treatment can prolong the survival time of the patients,the 5-year survival rate of ESCC after surgery is low (ranging from 14%-22%) [3]. The major causes leading to the poor prognosis of the ESCC patients is tumor metastasis. Therefore, any insight into the mechanisms of ESCC cell progression and metastasis may provide important clues for the development of therapeutics [4].Prenylated Rab acceptor 1 domain family member 3 (PRAF3, also known a
%U http://www.biomedcentral.com/1471-2407/12/97